Currently a Managing Partner and founder of LSP. His prime focus and responsibility within LSP is to invest in unlisted securities and the general management of the firm Board member of Kiadis Pharma, Orphazyme, Oxthera and Pharvaris Prior to establishing LSP, Martijn ran another investment firm where he was responsible for investments in the healthcare sector Among others, Martijn served as a Director of Prosensa (NL, IPO 2013, sold to Biomarin), Movetis (BEL, IPO in 2009, sold to Shire), Crucell (NL, IPO in 2000, sold to Johnson & Johnson), Rhein Biotech (NL, IPO in 1999, sold to Berna Biotech), and Qiagen (GER, IPO in 1996)
Management